Top

Published in:

01-10-2015 | Review Article

Advanced MR Imaging in Neuro-oncology

Authors: A. Radbruch, M. Bendszus

Published in: Clinical Neuroradiology | Special Issue 2/2015

Abstract

The value of magnetic resonance (MR) imaging for the clinical management of brain tumour patients has greatly increased in recent years through the introduction of functional MR sequences. Previously, MR imaging for brain tumours relied for the most part on contrast-enhanced T1-weighted MR sequences but today with the help of advanced functional MR sequences, the pathophysiological aspects of tumour growth can be directly visualised and investigated. This article will present the pathophysiological background of the MR sequences relevant to neuro-oncological imaging as well as potential clinical applications. Ultimately, we take a look at possible future developments for ultra-high-field MR imaging.

Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014;16 Suppl 7:2–11.CrossRef

Niendorf HP, Laniado M, Semmler W, Schörner W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol. 1987;8(5):803–15.PubMed

Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684–92.CrossRefPubMed

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology. 2014;83(3):227–34.CrossRefPubMed

Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol. 2011;13(9):1020–9.CrossRefPubMedCentralPubMed

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefPubMed

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.PubMed

Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2012;14(2):222–9.CrossRefPubMedCentralPubMed

Reichenbach JR, Haacke EM. High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed. 2001;14(7–8):453–67.CrossRefPubMed

10.

Reichenbach JR, Venkatesan R, Schillinger DJ, Kido DK, Haacke EM. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology. 1997;204(1):272–7.CrossRefPubMed

11.

Kim HS, Jahng GH, Ryu CW, Kim SY. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol. 2009;30(8):1574–9.CrossRefPubMed

12.

Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30(7):1402–8.CrossRefPubMed

13.

Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One. 2013;8(3):e57924.CrossRefPubMedCentralPubMed

14.

Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014;272(3):843–50.CrossRefPubMed

15.

Radbruch A, Graf M, Kramp L, Wiestler B, Floca R, Bäumer P, Roethke M, Stieltjes B, Schlemmer HP, Heiland S, Bendszus M. Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3 T. Eur J Radiol. 2012;81(12):4064–8.CrossRefPubMed

16.

Mohammed W, Xunning H, Haibin S, Jingzhi M. Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: a review. Cancer Imaging. 2013;13:186–95.CrossRefPubMedCentralPubMed

17.

Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(4):480–9.CrossRefPubMedCentralPubMed

18.

Schweser F, Deistung A, Lehr BW, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys. 2010;37(10):5165–78.CrossRefPubMed

19.

Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25(5):746–55.PubMed

20.

Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490–8.CrossRefPubMedCentralPubMed

21.

Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S. Early perfusion changes in patients with recurrent high-grade brain tumor treated with bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res. 2012;31:33.CrossRefPubMedCentralPubMed

22.

Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 2015;17:1139–47.CrossRefPubMed

23.

Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28(13):2293–9.CrossRefPubMedCentralPubMed

24.

Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Bäumer P, Schlemmer HP, Wick A, Heiland S, Wick W, Bendszus M. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151–9.CrossRefPubMed

25.

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.CrossRefPubMed

26.

Heiland S, Wick W, Bendszus M. Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy? J Clin Oncol. 2010. 28(29):e591. (author reply e592).CrossRefPubMed

27.

Radbruch A, Bendszus M, Wick W, Heiland S. Comment to: Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma: pitfalls in perfusion MRI in brain tumors: Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. J Clin Oncol. 2010;28:2293–9. Clin Neuroradiol. 2010;20(3):183–4.CrossRefPubMed

28.

Blasel S, Jurcoane A, Franz K, Morawe G, Pellikan S, Hattingen E. Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochir (Wien). 2010;152(11):1893–9.CrossRef

29.

Stecco A, Pisani C, Quarta R, Brambilla M, Masini L, Beldì D, Zizzari S, Fossaceca R, Krengli M, Carriero A. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma. J Neurooncol. 2011;102(2):261–71.CrossRefPubMed

30.

Hakyemez B, Erdogan C, Gokalp G, Dusak A, Parlak M. Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clin Radiol. 2010;65(1):15–20.CrossRefPubMed

31.

Xu XX, Li B, Yang HF, Du Y, Li Y, Wang WX, Zheng HJ, Gong QY. Can diffusion-weighted imaging be used to differentiate brain abscess from other ring-enhancing brain lesions? A meta-analysis. Clin Radiol. 2014;69(9):909–15.CrossRefPubMed

32.

Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L, Becker DP, Vinters HV, Alger JR. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000;50(3):215–26.CrossRefPubMed

33.

Sugahara T KY, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1):53–60.CrossRefPubMed

34.

Gupta R, Sinha U, Cloughesy TF, Alger JR. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med. 1999;41:2–7.CrossRefPubMed

35.

Lutz K, Wiestler B, Graf M, Bäumer P, Floca R, Schlemmer HP, Heiland S, Wick W, Bendszus M, Radbruch A. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. J Magn Reson Imaging. 2014;39(5):1096–103.CrossRefPubMed

36.

Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182–9.CrossRefPubMed

37.

Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882–9.CrossRefPubMed

38.

Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology. 2004;232(2):451–60.CrossRefPubMed

39.

Deng Z, Yan Y, Zhong D, Yang G, Tang W, Lü F, Xie B, Liu B. Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci. 2010;17(12):1530–6.CrossRefPubMed

40.

Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012;264(3):834–43.CrossRefPubMed

41.

Radbruch A, Schlemmer HP. Application of ultrahigh-field MRI in neuro-oncology. Radiologe. 2013;53(5):411–4.CrossRefPubMed

42.

Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol. 2015;36:1204–15.CrossRefPubMed

43.

Radbruch A, Eidel O, Wiestler B, Paech D, Burth S, Kickingereder P, Nowosielski M, Bäumer P, Wick W, Schlemmer HP, Bendszus M, Ladd M, Nagel AM, Heiland S. Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 T: a feasibility study. PLoS One. 2014;9:e110727.

44.

Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol. 2011;46(9):539–47.CrossRefPubMed

45.

Nagel AM, Lehmann-Horn F, Weber MA, Jurkat-Rott K, Wolf MB, Radbruch A, Umathum R, Semmler W. In vivo 35Cl MR imaging in humans: a feasibility study. Radiology. 2014;271(2):585–95.CrossRefPubMed

46.

Hoffmann SH, Radbruch A, Bock M, Semmler W, Nagel AM. Direct (17)O MRI with partial volume correction: first experiences in a glioblastoma patient. MAGMA. 2014;27(6):579–87.CrossRefPubMed

47.

Paech D, Zaiss M, Meissner JE, Windschuh J, Wiestler B, Bachert P, Neumann JO, Kickingereder P, Schlemmer HP, Wick W, Nagel AM, Heiland S, Ladd ME, Bendszus M, Radbruch A. Nuclear Overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 T in glioblastoma patients. PLoS One. 2014;9(8):e104181.CrossRefPubMedCentralPubMed

48.

Windschuh J, Zaiss M, Meissner JE, Paech D, Radbruch A, Ladd ME, Bachert P. Correction of B1-inhomogeneities for relaxation-compensated CEST imaging at 7 T. NMR Biomed. 2015;28(5):529–37.CrossRefPubMed

49.

Zaiss M, Windschuh J, Paech D, Meissner JE, Burth S, Schmitt B, Kickingereder P, Wiestler B, Wick W, Bendszus M, Schlemmer HP, Ladd ME, Bachert P, Radbruch A. Relaxation-compensated CEST-MRI of the human brain at 7 T: unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage. 2015;112:180–8.CrossRefPubMed

50.

Zaiss M, Kunz P, Goerke S, Radbruch A, Bachert P. MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed. 2013;26(12):1815–22.CrossRefPubMed

Title: Advanced MR Imaging in Neuro-oncology
Authors: A. Radbruch
M. Bendszus
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Neuroradiology / Issue Special Issue 2/2015
Print ISSN: 1869-1439
Electronic ISSN: 1869-1447
DOI: https://doi.org/10.1007/s00062-015-0439-2

At a glance: The STEP trials

Springer Medicine

Advanced MR Imaging in Neuro-oncology

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2015

Qualitätssicherung in der interventionellen Neuroradiologie

European Society of Minimally Invasive Neurological Therapy (ESMINT)

Foreword to this Anniversary Publication by the German Society of Neuroradiology

Differential Diagnosis of Acute Myelopathies: An Update

The Past, Present and Future of Endovascular Aneurysm Treatment

Evolution of Embolic Agents in Interventional Neuroradiology